1.Development and Validation of an HPLC-DAD Method for Simultaneous Quantitation of Steppogenin and Flavonoids from the Stems of Morus alba
Nguyen Viet PHONG ; You Mie LEE ; Byung Sun MIN ; Jeong Ah KIM
Natural Product Sciences 2024;30(2):65-71
Morus alba L. is well-known for its medicinal and economic value, particularly in Asian countries. Among the isolated compounds from this plant, steppogenin is exhibited as a flavonoid with promising pharmacological properties. This study focused on isolating bioactive compounds, notably steppogenin, from the ethyl acetate extract of M. alba. Additionally, a high-performance liquid chromatography-diode array detector (HPLC-DAD) method for the simultaneous quantification of steppogenin and isolated compounds was developed and validated. The calibration curve showed excellent linearity, with a correlation coefficient (R 2 ) value greater than 0.9957. The limit of detection (LOD) ranged from 0.006 to 0.018 μg/mL, whereas the limit of quantification (LOQ) ranged from 0.020 to 0.061 μg/mL. In precision tests conducted intra-day and inter-day, the accuracy was between 97.32% and 106.39%, with relative standard deviations (RSD) less than 2.27% and 1.65%, respectively. The presence of steppogenin and other flavonoids was confirmed by the study, contributing to the understanding of the chemical composition of M. alba. This validated analytical method offers a reliable means of quantifying steppogenin and aiding future research into its therapeutic potential.
2.Inhibition of α-Glucosidase by Abietane-Type Diterpenoids Isolated from Roots of Salvia miltiorrhiza
Nguyen Viet PHONG ; Le Thi THANH ; Mi Jeong KWON ; You Mie LEE ; Byung Sun MIN ; Jeong Ah KIM
Natural Product Sciences 2023;29(4):349-356
Salvia miltiorrhiza is a traditional medicinal plant used in Asian medicine for various therapeutic purposes. This plant contains numerous bioactive secondary metabolites, particularly abietane-type diterpenoids. In this study, 16 abietane-type diterpenoids were isolated from S. miltiorrhiza root extracts and structurally identified through advanced spectroscopic techniques. Among them, tanshinone IIA (6) and 15,16-dihydrotanshinone I (11) exhibited potent α-glucosidase inhibition, with IC 50 values of 48.38 ± 0.57 and 48.02 ± 0.47 µM, respectively. Enzyme kinetic studies revealed that these compounds served as non-competitive inhibitors of α-glucosidase. Our findings indicate that natural compounds from S. miltiorrhiza show promise as safe and effective α-glucosidase inhibitors, providing an alternative approach to diabetes treatment. This study contributes to the growing interest in utilizing natural sources for α-glucosidase inhibition and their potential application in healthcare and disease management.
3.Expression of ICAM-1 in Blood Vascular Endothelium and Tissues in Human Premalignant Lesion and Gastric/Hepatocellular Carcinomas
Li KANG ; Moonsik KIM ; You Mie LEE
The Korean Journal of Gastroenterology 2022;79(4):170-176
Background/Aims:
Angiogenesis is essential for the outgrowth and metastasis of tumors. The structure and characteristics of tumor vasculature differ from those of normal vessels. We compared the characteristics of differentially expressed genes in endothelial cells (ECs) isolated from gastric and normal cells.
Methods:
Previously, we had isolated pure tumor ECs (TECs) and normal ECs (NECs) from advanced gastric cancer (AGC) lesions and normal mucosal tissues, respectively. Using the oligomer chip platform of the Affymetrix GeneChip technology, genes that were expressed more than three-fold with a significance of p≤0.001 were measured. The intercellular adhesion molecule 1 (ICAM-1) was found to be overexpressed in the TECs compared to the normal gastric ECs. In this study, the upregulation of ICAM-1 was confirmed in cultured TECs by immunofluorescence.
Results:
The expression of ICAM-1 was upregulated in the ECs, as well as in the stromal and immune cells, in early human gastric preneoplastic and hepatic fibrotic tissues. Upregulation of ICAM-1 was observed in the TECs, immune cells, and cancer epithelial cells in AGC and hepatocellular carcinoma (HCC). These results suggest that increased ICAM-1 expression in the ECs of the tissue microenvironment progressively contributes to the recruitment of immune cells to promote inflammation, leading to fibrosis and tumorigenesis.
Conclusions
Therefore, upregulated ICAM-1 in the tissues in premalignant gastric diseases or hepatic fibrosis and their malignant cancers could be a promising target for disease prevention and treatment.
4.Protective effect of butylated hydroxylanisole against hydrogen peroxide-induced apoptosis in primary cultured mouse hepatocytes.
Geun Hye HWANG ; Yu Jin JEON ; Ho Jae HAN ; Soo Hyun PARK ; Kyoung Min BAEK ; Woochul CHANG ; Joong Sun KIM ; Lark Kyun KIM ; You Mie LEE ; Sangkyu LEE ; Jong Sup BAE ; Jun Goo JEE ; Min Young LEE
Journal of Veterinary Science 2015;16(1):17-23
Butylated hydroxyanisole (BHA) is a synthetic phenolic compound consisting of a mixture of two isomeric organic compounds: 2-tert-butyl-4-hydroxyanisole and 3-tert-butyl-4-hydroxyanisole. We examined the effect of BHA against hydrogen peroxide (H2O2)-induced apoptosis in primary cultured mouse hepatocytes. Cell viability was significantly decreased by H2O2 in a dose-dependent manner. Additionally, H2O2 treatment increased Bax, decreased Bcl-2, and promoted PARP-1 cleavage in a dose-dependent manner. Pretreatment with BHA before exposure to H2O2 significantly attenuated the H2O2-induced decrease of cell viability. H2O2 exposure resulted in an increase of intracellular reactive oxygen species (ROS) generation that was significantly inhibited by pretreatment with BHA or N-acetyl-cysteine (NAC, an ROS scavenger). H2O2-induced decrease of cell viability was also attenuated by pretreatment with BHA and NAC. Furthermore, H2O2-induced increase of Bax, decrease of Bcl-2, and PARP-1 cleavage was also inhibited by BHA. Taken together, results of this investigation demonstrated that BHA protects primary cultured mouse hepatocytes against H2O2-induced apoptosis by inhibiting ROS generation.
Animals
;
Apoptosis/*drug effects
;
Butylated Hydroxyanisole/chemistry/*pharmacology
;
Cell Survival/drug effects
;
Cells, Cultured
;
Hepatocytes/*drug effects
;
Hydrogen Peroxide/*toxicity
;
Male
;
Mice
;
Mice, Inbred ICR
;
Molecular Structure
5.Glyceollins, a novel class of soybean phytoalexins, inhibit SCF-induced melanogenesis through attenuation of SCF/c-kit downstream signaling pathways.
Experimental & Molecular Medicine 2013;45(4):e17-
The anti-melanogenesis effect of glyceollins was examined by melanin synthesis, tyrosinase activity assay in zebrafish embryos and in B16F10 melanoma cells. When developing zebrafish embryos were treated with glyceollins, pigmentation of the embryos, melanin synthesis and tyrosinase activity were all decreased compared with control zebrafish embryos. In situ expression of a pigment cell-specific gene, Sox10, was dramatically decreased by glyceollin treatment in the neural tubes of the trunk region of the embryos. Stem cell factor (SCF)/c-kit signaling pathways as well as expression of microphthalmia-associated transcription factor (MITF) were determined by western blot analysis. Glyceollins inhibited melanin synthesis, as well as the expression and activity of tyrosinase induced by SCF, in a dose-dependent manner in B16F10 melanoma cells. Pretreatment of B16F10 cells with glyceollins dose-dependently inhibited SCF-induced c-kit and Akt phosphorylation. Glyceollins significantly impaired the expression and activity of MITF. An additional inhibitory function of glyceollins was to effectively downregulate intracellular cyclic AMP levels stimulated by SCF in B16F10 cells. Glyceollins have a depigmentation/whitening activity in vitro and in vivo, and that this effect may be due to the inhibition of SCF-induced c-kit and tyrosinase activity through the blockade of downstream signaling pathway.
Animals
;
Embryo, Nonmammalian/drug effects
;
Melanins/*biosynthesis
;
Melanoma, Experimental/metabolism/pathology
;
Mice
;
Monophenol Monooxygenase/metabolism
;
Phosphorylation/drug effects
;
Pigmentation/drug effects
;
Proto-Oncogene Proteins c-kit/*metabolism
;
Pterocarpans/chemistry/*pharmacology
;
SOXE Transcription Factors/metabolism
;
Sesquiterpenes/chemistry/*pharmacology
;
Signal Transduction/*drug effects
;
Soybeans/*chemistry
;
Stem Cell Factor/*pharmacology
;
Zebrafish/embryology/metabolism
6.A 36 Year-Old Primivida Diagnosed with Primary Lung Cancer.
Sun Hye KO ; Hyeon Hui KANG ; Sun Mie YIM ; You Mi HWANG ; Eun Hye JI ; You Suk OH ; Sang Haak LEE
Korean Journal of Medicine 2012;82(1):85-89
A 36-year-old primivida, at 29 weeks of pregnancy with no smoking history, was admitted to the hospital complaining of cough for 3 days. Chest X-rays revealed atelectasis of the right upper lobe, and a transbronchial lung biopsy confirmed primary lung adenocarcinoma. After consulting with obstetricians and neonatologists, we wanted to deliver the child and treat the mother with chemoradiotherapy. But as she was adamantly opposed to treatment until fetal lung maturation was complete, we planned to delay the birth until 34 weeks, deliver the baby by caesarian section, and then treat the mother. However, maternal hypoxia and fetal distress resulted in an emergency delivery at 30 weeks. After delivery, we treated the mother's brain metastases with radiation therapy and systemic cisplatin-pemetrexed, but she deteriorated and expired 95 days after the diagnosis. Lung cancer during pregnancy is a rare disease and raises many medical and ethical issues in deciding the best course of therapy. We describe our clinical approach and review the potentially challenging features of managing a pregnant patient with lung cancer.
Adenocarcinoma
;
Adult
;
Anoxia
;
Biopsy
;
Brain
;
Chemoradiotherapy
;
Child
;
Cough
;
Emergencies
;
Fetal Distress
;
Humans
;
Lung
;
Lung Neoplasms
;
Mothers
;
Neoplasm Metastasis
;
Parturition
;
Pregnancy
;
Pulmonary Atelectasis
;
Rare Diseases
;
Smoke
;
Smoking
;
Thorax
7.Induction of Remission is Difficult due to Frequent Relapse during Tapering Steroids in Korean Patients with Polymyalgia Rheumatica.
Hyoun Ah KIM ; Jisoo LEE ; You Jung HA ; Sang Hyon KIM ; Chan Hee LEE ; Hyo Jin CHOI ; Han Joo BAEK ; Mie Jin LIM ; Won PARK ; Sungiae CHOI ; Yeon Sik HONG ; Yoo Hyun LEE ; Bo Ram KOH ; Chang Hee SUH
Journal of Korean Medical Science 2012;27(1):22-26
Polymyalgia rheumatica is an inflammatory disease affecting elderly and involving the shoulder and pelvic girdles. No epidemiological study of polymyalgia rheumatica was conducted in Korea. We retrospectively evaluated patients with polymyalgia rheumatica followed up at the rheumatology clinics of 10 tertiary hospitals. In total 51 patients, 36 patients (70.6%) were female. Age at disease onset was 67.4 yr. Twenty-three patients (45.1%) developed polymyalgia rheumatica in winter. Shoulder girdle ache was observed in 45 patients (90%) and elevated erythrocyte sedimentation rate (> 40 mm/h) in 49 patients (96.1%). Initial steroid dose was 23.3 mg/d prednisolone equivalent. Time to normal erythrocyte sedimentation rate was 4.1 months. Only 8 patients (15.7%) achieved remission. Among 41 patients followed up, 28 patients (68.3%) had flare at least once. Number of flares was 1.5 +/- 1.6. The frequency of flare was significantly lower in patients with remission (P = 0.02). In Korea, polymyalgia rheumatica commonly develops during winter. Initial response to steroid is fairly good, but the prognosis is not benign because remission is rare with frequent relapse requiring long-term steroid treatment.
Aged
;
Aged, 80 and over
;
Anti-Inflammatory Agents/administration & dosage/*therapeutic use
;
Blood Sedimentation
;
Cohort Studies
;
Female
;
Humans
;
Male
;
Middle Aged
;
Polymyalgia Rheumatica/*drug therapy/epidemiology
;
Prognosis
;
Recurrence
;
Republic of Korea/epidemiology
;
Retrospective Studies
;
Seasons
;
Steroids/administration & dosage/*therapeutic use
8.A 36 Year-Old Primivida Diagnosed with Primary Lung Cancer
Sun Hye KO ; Hyeon Hui KANG ; Sun Mie YIM ; You Mi HWANG ; Eun Hye JI ; You Suk OH ; Sang Haak LEE
Korean Journal of Medicine 2012;82(1):85-89
A 36-year-old primivida, at 29 weeks of pregnancy with no smoking history, was admitted to the hospital complaining of cough for 3 days. Chest X-rays revealed atelectasis of the right upper lobe, and a transbronchial lung biopsy confirmed primary lung adenocarcinoma. After consulting with obstetricians and neonatologists, we wanted to deliver the child and treat the mother with chemoradiotherapy. But as she was adamantly opposed to treatment until fetal lung maturation was complete, we planned to delay the birth until 34 weeks, deliver the baby by caesarian section, and then treat the mother. However, maternal hypoxia and fetal distress resulted in an emergency delivery at 30 weeks. After delivery, we treated the mother's brain metastases with radiation therapy and systemic cisplatin-pemetrexed, but she deteriorated and expired 95 days after the diagnosis. Lung cancer during pregnancy is a rare disease and raises many medical and ethical issues in deciding the best course of therapy. We describe our clinical approach and review the potentially challenging features of managing a pregnant patient with lung cancer.
Adenocarcinoma
;
Adult
;
Anoxia
;
Biopsy
;
Brain
;
Chemoradiotherapy
;
Child
;
Cough
;
Emergencies
;
Fetal Distress
;
Humans
;
Lung
;
Lung Neoplasms
;
Mothers
;
Neoplasm Metastasis
;
Parturition
;
Pregnancy
;
Pulmonary Atelectasis
;
Rare Diseases
;
Smoke
;
Smoking
;
Thorax
9.Usefulness of Stent Implantation for Treatment of Intracranial Atherosclerotic Stenoses.
Kuk Seon KIM ; Dae Hyun HWANG ; Young Hwan KO ; Ik Won KANG ; Eil Seong LEE ; You Mie HAN ; Sun Jung MIN ; In Soo KIM ; Choon Woong HUR ; Shiyi LUI ; Tong LIN ; Tongfu YOU ; Haibin SHI ; Linsun LI
Neurointervention 2012;7(1):27-33
PURPOSE: We evaluated the usefulness of intracranial stent implantation for treating patients with atherosclerotic stenosis and with recurrent, ischemic, neurological symptoms despite having undergone medical therapy. MATERIALS AND METHODS: Between March 2004 and April 2010, we attempted intracranial, stent-assisted angioplasty in 77 patients with 85 lesions (anterior circulation 73 cases, posterior circulation 12 cases) and who had ischemic neurological symptoms with more than 50% major cerebral artery stenosis. We analyzed the results regarding the technical success rate, complication rate, and restenosis rate during the mean 29.4 month follow-up period. RESULTS: Intracranial stent implantation was successfully performed in 74 cases (87.1%). In nine cases among the 11, failed cases, stent implantation failure was due to the tortuosity of the target vessel. One patient experienced middle cerebral artery rupture during the procedure, and we embolized the vessel using a microcoil. Five patients developed cerebral infarction in three weeks after the procedure, three of whom improved using conservative management, although the other, two patients expired. The mean number of residual stenoses decreased from 72.3% to 14.7%. Three patients demonstrated significant in-stent restenosis, i.e. more than 50%, during the follow-up period. CONCLUSION: As stent-assisted angioplasty in intracranial, atherosclerotic stenosis is effective and relatively safe, it can be considered as an alternative treatment for patients with recurrent, ischemic, neurologic symptoms despite having undergone medical therapy.
Angioplasty
;
Cerebral Arteries
;
Cerebral Infarction
;
Constriction, Pathologic
;
Follow-Up Studies
;
Glycosaminoglycans
;
Humans
;
Intracranial Arteriosclerosis
;
Middle Cerebral Artery
;
Neurologic Manifestations
;
Rupture
;
Stents
10.Analysis of Patients with Positive Acid-fast Bacilli Culture and Negative T-SPOT.TB Results.
You Mie HAN ; Hyun Soo KIM ; Cheol Hong KIM ; Hee Jung KANG ; Kyu Man LEE
The Korean Journal of Laboratory Medicine 2010;30(4):414-419
BACKGROUND: T-SPOT.TB is a sensitive test that detects interferon-gamma producing T-cells in tuberculosis patients following stimulation with tuberculosis-specific antigens. Our study was aimed to investigate the possible causes of false negative results of the test by analyzing the patients with positive acid-fast bacilli (AFB) culture and negative T-SPOT.TB results. METHODS: We investigated 138 patients with positive AFB culture results reported between January 2009 and April 2010. Medical records of these patients were reviewed for the results of T-SPOT.TB test, AFB culture, PCR for Mycobacterium tuberculosis (TB-PCR), chest X-ray, drug treatment, etc. Diagnosis of tuberculosis was confirmed by positive TB-PCR or identification of Mycobacterium tuberculosis (MTB). Sensitivity of T-SPOT.TB test was calculated and the possible causes of AFB culture positive and T-SPOT.TB negative results were analyzed. RESULTS: T-SPOT.TB test was performed in 63 of the 138 patients with AFB culture positive results. Fifty-six (88.9%) were positive and 7 patients (11.1%) were negative on T-SPOT.TB test. Of these 7 negative cases, 4 were confirmed as nontuberculous mycobacteria (NTM), 2 were suspected as NTM and diagnosis could not be confirmed in 1. Six of these 7 patients were over 70 yr old and 6 patients had lymphocytopenia. T-SPOT.TB negative results were not observed in any of the 44 patients confirmed to have active tuberculosis (sensitivity 100%). CONCLUSIONS: Our results suggest that T-SPOT.TB test is very sensitive for diagnosing active tuberculosis. NTM may be the main cause of AFB culture positive and T-SPOT.TB negative results, but MTB infection in immunocompromised patients also has to be considered.
Adult
;
Aged
;
Aged, 80 and over
;
Bacillus/*isolation & purification
;
Culture Media
;
Female
;
Humans
;
Lymphocyte Count
;
Lymphopenia/diagnosis/microbiology
;
Male
;
Polymerase Chain Reaction
;
Reagent Kits, Diagnostic
;
Sensitivity and Specificity
;
Tuberculosis/*diagnosis/microbiology/radiography

Result Analysis
Print
Save
E-mail